Authors:  Aude Fahrer, George Cavic, Christina Carroll, Andrew Almonte, Birhanu Jemere, Yada Kanjanapan, Laeeq Malik, Desmond Yip

Our team previously initiated the first ever investigator-led phase I oncology trial in the ACT.

Our novel, slow-release cancer immunotherapy is injected into a tumour to initiate a strong immune response.  The objective is to convert the tumour into a personalised anti-cancer vaccine.  

The objectives of our current project are to improve our formulation, and to see if our drug acts synergistically with checkpoint inhibitor cancer therapies.  Our ultimate aim is to improve response rates to treatment for cancer patients.